Our Goal is to Transform Care for Patients with GIST
We are committed to transforming the lives of patients with GIST. At IDRx, we believe that the best treatments for patients target the full range of tumor biology.
IDRX is inspired by the success of therapies that address the full range of disease mechanisms, and that have delivered transformative benefit to the lives of people living with serious conditions.
We are developing therapies to treat the large majority of GIST tumors driven by mutations in the KIT enzyme. This approach utilizes a primary therapy (IDRX-42) which has the potential to be the best-in-class treatment for these tumors. IDRX-42 is designed to potently inhibi both the primary mutations that drive the progression of most cases of GIST, and also the secondary mutations that contribute to loss of response to treatment. We are also pursuing a second therapy (IDRX-73) designed to selectively enhance activity against a key drug resistance mutation, which we hope will offer superior benefit to some patients. We aim to intervene earlier in the course of patients' disease, to address and prevent the emergence of these mutations. We believe this approach has the potential to offer prolonged, durable, and better tolerated therapeutic responses for people living with GIST.
Currently Enrolling Clinical Trials
IDRx is conducting a Phase 1 first-in-human study of IDRX-42, a small molecule tyrosine kinase inhibitor designed to target key genetic driver and resistance mutations in GIST. The study is currently enrolling adult participants with metastatic and/or unresectable GIST in the U.S. and Europe.